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Although the associations between dementia and ischemic stroke have been comprehensively described,1 fewer data 
are available for spontaneous intracerebral hemorrhage (ICH), 
in part because of its high case fatality.2,3 Cognitive impairment 
often develops in survivors of ICH who were previously dementia 
free, particularly if the ICH is lobar, and has been associated with 
baseline neuroimaging markers of cerebral amyloid angiopathy 
(CAA).2 In those presenting with ICH, cognitive impairment 
before the event is common, with an estimated pooled incidence 
of 16.7%,4 suggesting that the underlying neurovascular and neu-
ropathological processes that result in cognitive impairment after 
ICH might already be present at the time of initial presentation 
with ICH.2,4,5 However, it is not clear to what extent subsequent 
cognitive impairment after ICH is mediated by direct damage 
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from the index ICH, the effects of recurrent ICH, or the impact 
of the underlying small vessel disease (SVD)2,4; understanding 
the contribution of these mechanisms is potentially important in 
developing rational dementia prevention strategies.
We therefore investigated whether neuroimaging evidence of 
CAA (specifically, meeting the modified Boston criteria for proba-
ble CAA6 at presentation, and increases in a composite CAA score7) 
was associated with the presence of cognitive impairment before 
ICH. We then performed further analyses investigating the associa-
tions between individual magnetic resonance imaging (MRI) neu-
roimaging markers of SVD and cognitive impairment before ICH.
Materials and Methods
Patient Selection
We included patients recruited to a prospective multicentre observa-
tional cohort study of symptomatic patients with confirmed ICH (The 
Clinical Relevance of Microbleeds In Stroke Study; CROMIS-2). 
Those aged ≥18 years with an ICH confirmed on brain imaging (either 
computed tomography or MRI) were eligible, providing that there 
was no evidence that the ICH was because of an underlying structural 
cause or secondary to head trauma. This study has been preregistered, 
and the full details of the study protocol have been published pre-
viously.8 The study was approved by the National Research Ethics 
Service (IRAS reference 10/H0716/61). Written informed consent 
was obtained from each patient. The primary and substudy analyses 
for the CROMIS-2 study are ongoing; once all of these analyses are 
completed, the CROMIS-2 Steering Committee will consider appli-
cations from other researchers for access to anonymized source data.
The Informant Questionnaire for Cognitive Decline in the Elderly 
(IQCODE) is a validated questionnaire given to a patient’s family 
member or caregiver which aims to establish whether there have been 
specific changes in cognitive and functional performance over the pre-
ceding 10-year time period.9–11 Specifically, the informant was asked to 
compare the patient’s performance from 10 years ago with their per-
formance just before their stroke. The 16-item IQCODE was requested 
for all participants (score range, 1.0–5.0); this version of the IQCODE 
has been reported to have similar accuracy to the original 26-item ver-
sion.10 We defined pre-ICH cognitive impairment as an IQCODE score 
of >3.3, based on previously reported pooled sensitivity and specificity 
values for detecting cognitive impairment from a meta-analysis investi-
gating IQCODE accuracy in a general hospital setting.10
For inclusion in the final analysis, it was necessary for patients to 
have an IQCODE from the time of their admission, together with the 
MRI sequences needed for imaging analysis (described below).
Imaging Acquisition and Analysis
Imaging was undertaken at each study center according to local pro-
tocols, and all brain imaging performed as part of the participant’s 
standard clinical care was sent to the study’s coordinating center in 
anonymized DICOM format.
Imaging analysis was performed by 2 clinical research associates 
(D.W., G.B.) and 2 MSc students (K.O.-B.A, S.L.), all of whom were 
trained in neuroimaging rating and blinded to the participant clinical 
details. All structural imaging markers of cerebral SVD were rated 
in accordance with the Standards for Reporting Vascular Changes on 
Neuroimaging consensus criteria.12 Only those with an available MRI 
and all of the necessary sequences for cerebral SVD rating (ie, axial 
T2, axial or coronal fluid-attenuated inversion recovery (FLAIR), 
and a blood-sensitive sequence) were included in the neuroimaging 
marker analysis.
Lacunes were identified and counted (D.W.) on T2 and FLAIR 
sequences.12 Cerebral microbleeds were rated (D.W.) using blood-sen-
sitive (T2* weighted or susceptibility weighted images) sequences and 
the validated Microbleed Anatomical Rating Scale.13 MRI-visible peri-
vascular spaces (PVS) in the centrum semiovale (CSO-PVS) and basal 
ganglia (BG-PVS) were defined and rated (G.B.) on T2 and FLAIR 
sequences using a validated 4-point visual rating scale12,14,15on a single 
predefined slice (first slice above the anterior commissure for the basal 
ganglia, and the first slice above the level of the lateral ventricles for 
the centrum semiovale). The hemisphere contralateral to the ICH was 
preferentially rated. White matter hyperintensities (WMH; also termed 
leukoaraiosis) were rated (K.O.-B.A.) on T2 and FLAIR sequences 
using the Fazekas scale.16,17 Cortical superficial siderosis (cSS) was 
identified on blood-sensitive sequences and classified (D.W.) as either 
focal (involving ≤3 sulci) or disseminated (involving ≥4 sulci), in keep-
ing with previously described terminology.18 Medial temporal atrophy 
(MTA) was rated (G.B.) on T1 or FLAIR coronal images using the 
Scheltens visual scale.19,20 Global cortical atrophy (GCA) was rated 
(G.B.) using the Pasquier scale on axial T1 or FLAIR images. In cases 
where these sequences were not available, T2 images were used. For 
both MTA and GCA, there was good agreement between all sequences 
used (MTA κ=0.77; GCA κ=1.00). For both MTA and GCA, the hemi-
sphere contralateral to the ICH was preferentially rated.
ICH location was defined as infratentorial, deep, or lobar, with the 
latter in cortical or cortical–subcortical regions and not involving any 
of the deep grey matter structures. Hematoma volume was calculated 
(S.L.) using a previously described validated semiautomated plani-
metric method.21
A clinico-radiological diagnosis of probable CAA was based on 
meeting the modified Boston criteria.6
The CAA score was calculated from a previously described 
6-point scale.7 This scale awards 1 point for CSO-PVS rating of 
Table 1. Baseline Demographic and Clinical Characteristics
All IQCODE ≤3.3 IQCODE >3.3
Mean or Proportion 
Difference (95% CI) P Value
n (%) 166 125 (75.3) 41 (24.7) … …
Age, y, mean (SD) 68.9 (12.9) 67.0 (13.1) 74.5 (10.9) −7.5 (−11.9 to −3.0) 0.0012
Sex, male, n (%) 104 (62.7) 76 (60.8) 28 (68.3) −7.5 (−24.1 to 9.1) 0.389
Hypertension, presence, n (%) 96 (58.1) 75 (60.5) 21 (51.2) 9.3 (−8.3 to 26.8) 0.297
Hypercholesterolemia, presence, n (%) 58 (35.8) 37 (30.6) 21 (51.2) −20.6 (−38.0 to −3.3) 0.017
Diabetes mellitus, presence, n (%) 20 (12.1) 11 (8.9) 9 (22.0) −13.1 (−26.7 to 0.5) 0.026
Atrial fibrillation, presence, n (%) 33 (21.3) 22 (19.0) 11 (28.2) −9.2 (−25.1 to 6.6) 0.223
Previous ischemic stroke or TIA, presence, n (%) 29 (18.1) 18 (14.8) 11 (29.0) −14.2 (−29.9 to 1.5) 0.047
Previous ICH, presence, n (%) 9 (5.5) 4 (3.2) 5 (12.5) −9.3 (−20.0 to 1.4) 0.025
Percentage values were calculated using the total number of patients for whom data was available as the denominator. P values are from χ2 and 
independent t tests. Proportion differences and their confidence intervals are given as percentages. CI indicates confidence intervals; ICH, intracerebral 
hemorrhage; IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly; and TIA, transient ischemic attack.
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frequent-to-severe grades (ie, presence of >20 CSO-PVS) and WMH 
that is either Fazekas grade 3 if periventricular, or Fazekas grade ≥2 if 
deep.22 Additional points are awarded for the presence of lobar micro-
bleeds (1 point if 2–4 are present; 2 points if there are ≥5) and cSS (1 
point if focal; 2 points if disseminated).7
The SVD score was determined using a previously described 
4-point scale.22,23 This scale awards 1 point for the presence of lacu-
nes, microbleeds, BG-PVS rating of moderate-to-severe grades (ie, 
presence of >10 BG-PVS), and WMH that is either Fazekas grade 3 
if periventricular or Fazekas grade ≥2 if deep.22
Statistics
We investigated for selection bias within our final cohort by com-
paring the characteristics of people with appropriate MRI and those 
without. IQCODE was dichotomized using a cutoff of 3.3, and base-
line characteristics were compared (Table 1) for those with scores 
>3.3 (ie, with cognitive impairment) and those with scores ≤3.3. 
Continuous data were reviewed for normality, and if normally dis-
tributed we used the independent t test. Where continuous variables 
were not normally distributed, we used the (nonparametric) Mann–
Whitney U test. We used the χ2 tests for categorical variables. The 
independent t test (normally distributed continuous data) and the 
2-sample test of proportion (categorical data) were used to compare 
means and proportions, respectively.
Univariate comparisons were used to identify potential confound-
ers for inclusion in the multivariable models; all variables with 
P<0.05 were included. We then performed adjusted logistic regres-
sion analyses, adjusting for significant associations identified in 
univariate analyses (Table 2). In further analyses (Table 3), we inves-
tigated associations with other neuroimaging markers suggestive of 
CAA (the presence of strictly lobar microbleeds, and presentation 
with lobar ICH), as well as a composite SVD score and its component 
elements. In these analyses, each neuroimaging marker was consid-
ered individually (ie, each adjusted model included only 1 neuroim-
aging marker at a time). Given that these analyses were exploratory, 
we did not make an adjustment for multiple testing.
Statistical analysis was performed (G.B.) using Stata (Version 11.2).
Results
Cohort Characteristics
The demographic and imaging characteristics of those 
included (n=166) are shown in Table 1. Patients without MRI 
(n=588) and those with MRI but with missing or uninter-
pretable sequences (n=43) were excluded (online-only Data 
Supplement). When compared with the excluded patients 
(online-only Data Supplement), those included were younger 
(mean, 68.9 versus 75.0 years; P<0.00001), less likely to have 
hypertension (58.2% versus 70.9%; P=0.002), hypercholes-
terolemia (35.8% versus 47.9%; P=0.006), diabetes mellitus 
(12.1% versus 19.8%; P=0.024), and atrial fibrillation (12.3% 
versus 43.5%; P<0.0001), and more likely to have previously 
had an ischemic stroke or transient ischemic attack (24.7% ver-
sus 18.1%; P=0.081), lower Glasgow Coma Scale at presenta-
tion (interquartile range, 13–15 versus 14–15; P=0.003) and 
pre-ICH cognitive decline (38.2% versus 24.7%; P=0.001).
When comparing those with and without pre-ICH cogni-
tive decline, those with (n=41) were older (mean difference, 
Table 2. Univariable and Adjusted Logistic Regression 
Models, Investigating Associations Between Cognitive 
Impairment Before ICH and Evidence of CAA
Univariable OR 
(95% CI)
P 
Value
Adjusted OR 
(95% CI)
P 
Value
Meets modified 
Boston criteria for 
probable CAA
3.93 (1.72–8.96) 0.001 4.01 (1.53–10.51) 0.005
CAA score (per 
point increase)
1.45 (1.11–1.92) 0.007 1.42 (1.03–1.97) 0.033
All adjusted models incorporated the following variables: age at event, 
hypercholesterolemia, presence of diabetes mellitus, previous ischemic stroke 
or transient ischemic attack, and previous ICH. CAA indicates cerebral amyloid 
angiopathy; CI, confidence intervals; ICH, intracerebral hemorrhage; and OR, 
odds ratio.
Table 3. Logistic Regression Models (Univariable and Adjusted), Reviewing Associations Between Cognitive 
Impairment Before ICH and Individual Structural Markers of Cerebral SVD, and a Composite SVD Score
Univariable OR (95% CI) P Value Adjusted OR (95% CI) P Value
WMH; periventricular Fazekas 3 or deep Fazekas ≥2 
(presence)
2.31 (1.11–4.79) 0.024 2.03 (0.87–4.74) 0.103
Lacunes (presence) 1.18 (0.50–2.81) 0.702 … …
CSO-PVS (per grade increase) 0.77 (0.53–1.12) 0.168 … …
BG-PVS (per grade increase) 0.97 (0.53–1.80) 0.935 … …
Strictly lobar microbleeds (presence) 2.76 (1.21–6.30) 0.016 2.47 (0.95–6.37) 0.062
cSS (presence) 4.16 (1.55–11.12) 0.005 4.08 (1.28–13.05) 0.018
Presentation with lobar ICH 2.07 (1.00–4.28) 0.050 2.29 (0.99–5.31) 0.053
MTA (per grade increase) 1.33 (0.90–1.97) 0.150 … …
GCA (per grade increase) 1.35 (0.88–2.08) 0.169 … …
Hemorrhage volume, mL 0.98 (0.96–1.01) 0.210 … …
SVD score (per point increase) 1.52 (1.06–2.18) 0.021 1.36 (0.89–2.08) 0.150
Each model is independent, and considers only a single neuroimaging marker at a time. All adjusted models incorporated the following variables: 
age at event, hypercholesterolemia, presence of diabetes mellitus, previous ischemic stroke or transient ischemic attack, and previous ICH. BG 
indicates basal ganglia; CI, confidence interval; CSO, centrum semiovale; cSS, cortical superficial siderosis; GCA, global cortical atrophy; ICH, 
intracerebral hemorrhage; MTA; medial temporal atrophy; OR, odds ratio; PVS, MRI-visible perivascular space; SVD, small vessel disease; and WMH, 
white matter hyperintensities.
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7.5 years; P<0.0012) and more likely to have hypercholes-
terolemia (51.2% versus 30.6%; P=0.017), diabetes mellitus 
(22.0% versus 8.9%; P=0.026), previous ischemic stroke or 
transient ischemic attack (29.0% versus 14.8%; P=0.047), and 
previous ICH (12.5% versus 3.2%; P=0.025).
Associations With Pre-ICH Cognitive Decline: 
Univariate and Multivariate Analyses
Univariate logistic regression analyses showed that pre-ICH 
cognitive decline was associated with meeting the modified 
Boston criteria for probable CAA at presentation and increas-
ing CAA score (Table 2). In our multivariable analysis, we 
adjusted for age at event, hypercholesterolemia, presence 
of diabetes mellitus, previous ischemic stroke or transient 
ischemic attack, and previous ICH, which were statistically 
significant in univariate analyses (Table 1). Meeting the modi-
fied Boston criteria for probable CAA at presentation (odds 
ratio [OR], 4.01; 95% confidence interval [CI], 1.53–10.51); 
P=0.005) and increasing CAA score (for each point increase, 
OR, 1.42; 95% CI, 1.03–1.97; P=0.033) remained associated 
with pre-ICH cognitive decline (Table 2).
We then performed further analyses investigating the asso-
ciations between individual neuroimaging markers of SVD 
and cognitive impairment before ICH. In univariable analyses 
(Table 3), we identified associations between pre-ICH cogni-
tive decline and increasing SVD score, WMH, the presence of 
cSS, presence of strictly lobar microbleeds, and lobar ICH at 
presentation. In analyses adjusted for clinical and demographic 
variables identified in the univariate analysis (as above), the 
presence of cSS (OR, 4.08; 95% CI, 1.28–13.05; P=0.018), 
strictly lobar microbleeds (OR, 2.47; 95% CI, 0.95–6.37; 
P=0.062), and lobar ICH at presentation (OR, 2.29; 95% CI, 
0.99–5.31; P=0.053) showed associations with pre-ICH cog-
nitive impairment. The previous associations with increasing 
SVD score and WMH were no longer statistically significant, 
although for WMH a large effect size remained (OR, 2.03).
Discussion
Our main new finding is that MRI neuroimaging markers 
of CAA are associated with pre-ICH cognitive impairment. 
This suggests that cognitive impairment in CAA is not only 
because of brain injury caused directly by ICH but also inde-
pendently related to the underlying small vessel disruption 
associated with CAA.
Our findings add to growing evidence that CAA plays an 
important role in the development of cognitive impairment and 
dementia in those with ICH. The prevalence of pre-ICH demen-
tia in lobar ICH is near double that in deep ICH,24 and structural 
imaging markers of CAA (cSS, cerebral microbleeds) present at 
the time of ICH are associated with later progression to demen-
tia.2 Our results show that a composite CAA score has a per 
point association with cognitive decline; further studies could 
help establish whether such a score might be useful in patients 
with milder CAA (including those not fulfilling Boston criteria, 
or without macrohemorrhage). We found a strong association 
between cSS and pre-ICH cognitive impairment, suggest-
ing that leptomeningeal hemorrhage, rather than parenchymal 
microbleeds, might be an especially important pathological 
process impairing cognition in CAA. Our findings also con-
tribute to our understanding of the mechanisms by which CAA 
disrupts cognition, which include hematoma damage (via direct 
effects on cortical integrity and function2) and small vessel 
mechanisms. The latter may include effects on brain network 
efficiency,25 which correlates with cognitive performance and 
shows disturbances in the non-ICH hemisphere.26 Our finding 
that CAA is associated with cognitive impairment before ICH 
shows that hematoma damage cannot be the only mechanism 
contributing to cognitive disruption and supports the hypothesis 
that small vessel mechanisms are important.
A further possibility is that cognitive impairment before 
ICH is because of coincident Alzheimer’s disease.4 Although 
the co-occurrence of CAA and Alzheimer’s disease pathology 
is well recognized,27 CAA seems to have a cognitive profile 
distinct from that seen in Alzheimer’s disease, characterized 
primarily by deficits in processing speed and executive func-
tion.28,29 Recent neuropathological work30 found that CAA 
makes an independent contribution to cognitive performance in 
Alzheimer’s disease. Together, this evidence suggests that CAA 
has a specific neurovascular impact on cognitive performance, 
independent of coexistent Alzheimer’s pathology. Although 
we did not find an association between MTA or GCA (as puta-
tive imaging markers of Alzheimer’s pathology31) and pre-ICH 
cognitive impairment, we acknowledge that our sample size is 
small and so we cannot rule out missing subtle effects.
The main strength of this study is our detailed neuroimaging 
description of the structural markers of cerebral SVD in the con-
text of pre-ICH cognitive decline, in a richly phenotyped pro-
spective nationwide cohort of patients. However, our work also 
has limitations. Those included in our study were younger, with 
fewer comorbidities and a lower IQCODE than those who did 
not have an interpretable MRI; additionally, we acknowledge 
that a suspicion of CAA could increase the likelihood of an MRI 
being performed (50% of our included patients presented with 
lobar ICH), and so our final cohort might not be representative 
of those presenting with a spontaneous ICH to an acute stroke 
service. Brain imaging at each study center was completed 
according to local protocols, and so there are unavoidable varia-
tions in the nature and manner of the sequences obtained, which 
could influence our results. In particular, the use of suscepti-
bility-weighted versus T2*-weighted gradient echo sequences 
may result different microbleed counts, as the former is more 
sensitive to this; we did not adjust for this in our analyses. There 
are inherent limitations of using the IQCODE, including varia-
tions in the threshold used to define cognitive impairment and 
the lack of validation against a reference standard for prestroke 
cognitive impairment. Finally, we acknowledge that our study 
size is small, and so our results should be interpreted cautiously, 
particularly the adjusted analyses. As detailed, we chose not to 
apply an adjustment for multiple testing in order not to miss 
potential associations of interest. In addition, although our 
study is powered to detect moderate effect sizes, it may have 
missed smaller effects.
Cognitive impairment before ICH is common and is asso-
ciated with imaging findings consistent with an important 
contribution from CAA. This suggests that any future strategy 
aiming to reduce the impact of poststroke dementia in ICH will 
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need to extend beyond stroke prevention and include strategies 
that address the small vessel impact of CAA. Further work on 
the natural history of when and how CAA may influence an 
individual’s cognitive profile is a priority for future research.
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SUPPLEMENTARY MATERIAL 
 
Supplementary Table 
Baseline characteristics of those included and excluded subjects. P values are from chi-
squared and independent t-tests, except where indicated († for Mann-Whitney U test).  
 All with IQCODE 
Included in 
final analysis Excluded p value 
n 797 166 631 - 
Age, years, mean (SD) 73.7 (12.1) 68.9 (12.9) 75.0 (11.6) <0.00001 
Sex, female, n (%) 328 (41.2) 62 (37.4) 266 (42.2) 0.263 
Hypertension, presence, n (%) 539 (68.2) 96 (58.2) 443 (70.9) 0.002 
Hypercholesterolaemia, 
presence, n (%) 351 (45.4) 58 (35.8) 293 (47.9) 0.006 
Diabetes mellitus, presence, n 
(%) 144 (18.2) 20 (12.1) 124 (19.8) 0.024 
Atrial fibrillation, presence, n 
(%) 285 (38.8) 33 (21.3) 252 (43.5) <0.0001 
Previous ischaemic stroke or 
TIA, presence, n (%) 176 (23.3) 29 (18.1) 147 (24.7) 0.081 
Previous intracerebral 
haemorrhage, presence, n (%) 38 (4.9) 9 (5.5) 29 (4.7) 0.683 
GCS, median (IQR) 15 (14 – 15) 15 (14 – 15) 15 (13 – 15) 0.003† 
IQCODE, median (IQR) 3.12 (3.0 – 3.5) 3.0 (3.0 – 3.3) 3.13 (3.0 – 3.5) <0.00001† 
IQCODE > 3.3 282 (35.4) 41 (24.7) 241 (38.2) 0.001 
 
Abbreviations: GCS, Glasgow Coma Scale; IQCODE, Informant Questionnaire on Cognitive 
Decline in the Elderly; IQR, interquartile range; SD, standard deviation; TIA, transient 
ischaemic attack. 
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Supplementary Figure 
Description of the study population.  
Only those with an available MRI and the necessary sequences for cerebral small vessel 
disease rating (i.e. axial T2, axial and/or coronal FLAIR, and a blood sensitive sequence) 
were included in the neuroimaging marker analysis. 
 
 
 
 
Abbreviations: CROMIS-2, Clinical Relevance of Microbleeds in Stroke Study; ICH, 
intracerebral haemorrhage; IQCODE, Informant Questionnaire on Cognitive Decline in the 
Elderly. 
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
 Item 
No Recommendation 
Title and abstract 1  (a) Indicate the study’s design with a commonly used term in 
the title or the abstract 
 (b) Provide in the abstract an informative and balanced summary 
of what was done and what was found 
Introduction 
Background/rationale 2  Explain the scientific background and rationale for the 
investigation being reported 
Objectives 3  State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4  Present key elements of study design early in the paper 
Setting 5  Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data collection 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and 
methods of selection of participants. Describe methods of follow-up 
 Case-control study—Give the eligibility criteria, and the sources 
and methods of case ascertainment and control selection. Give the 
rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources 
and methods of selection of participants 
(b) Cohort study—For matched studies, give matching criteria and 
number of exposed and unexposed 
 Case-control study—For matched studies, give matching criteria 
and the number of controls per case 
Variables 7  Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
Data sources/ 
measurement 
8*   For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Bias 9  Describe any efforts to address potential sources of bias 
Study size 10  Explain how the study size was arrived at 
Quantitative variables 11  Explain how quantitative variables were handled in the analyses. 
If applicable, describe which groupings were chosen and why 
Statistical methods 12  (a) Describe all statistical methods, including those used to 
control for confounding 
 (b) Describe any methods used to examine subgroups and 
interactions 
 (c) Explain how missing data were addressed 
(d) Cohort study—If applicable, explain how loss to follow-up was 
addressed 
 Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods 
taking account of sampling strategy 
 (e) Describe any sensitivity analyses 
Continued on next page  
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Results 
Participants 13*  (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
 (b) Give reasons for non-participation at each stage 
 (c) Consider use of a flow diagram 
Descriptive 
data 
14*  (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
 (b) Indicate number of participants with missing data for each variable of 
interest 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
 Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary 
measures 
Main results 16  (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
 (b) Report category boundaries when continuous variables were 
categorized 
 (c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
Other analyses 17  Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
Discussion 
Key results 18  Summarise key results with reference to study objectives 
Limitations 19  Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
Interpretation 20  Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
Generalisability 21  Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22  Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present article is 
based 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for 
exposed and unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 
Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at 
www.strobe-statement.org. 
 
